Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Primary Mediastinal Large B-Cell Lymphoma Refractory: early-phase trial registry
1 of 2 indexed Primary Mediastinal Large B-Cell Lymphoma Refractory trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Primary Mediastinal Large B-Cell Lymphoma Refractory: 2 US clinical trials tracked, 1 recruiting.
Primary Mediastinal Large B-Cell Lymphoma Refractory is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Jennifer Crombie, MD, running 1 of these trials.
Enrollment posture brief
Registry condition primary-mediastinal-large-b-cell-lymphoma-refractory
OPEN 1 | RECR 50% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Primary Mediastinal Large B-Cell Lymphoma Refractory lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Primary Mediastinal Large B-Cell Lymphoma Refractory on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Primary Mediastinal Large B-Cell Lymphoma Refractory is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
Pembro Plus CAR T-cell Therapy in R/R in PMBCL
Jennifer Crombie, MD
NCT05934448
A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)
Merck Sharp & Dohme
NCT06504394
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Primary Mediastinal Large B-Cell Lymphoma Refractory records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Primary Mediastinal Large B-Cell Lymphoma Refractory trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Primary Mediastinal Large B-Cell Lymphoma Refractory page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Primary Mediastinal Large B-Cell Lymphoma Refractory trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Jennifer Crombie, MD sponsors the most Primary Mediastinal Large B-Cell Lymphoma Refractory trials on record, review their full trial history before evaluating a specific study. See Jennifer Crombie, MD's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Primary Mediastinal Large B-Cell Lymphoma Refractory condition card totals 2 registered trials; most-linked intervention Pembrolizumab (+) Berahyaluronidase alfa; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.